Generics 12

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Aprepitant manufacturers

12 products found

Filters

Filters

Filters , active

Country of origin : India

Clear all

12 products found

aprepitant

Capsules 80 mg, 125 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Available for
Licensing with supply, Distribution only
Manufacturer #17708
This pharmaceutical company boasts over 75 years of experience in manufacturing, research & development, and global supply chain management for specialty pharmaceuticals. They have introduced over 100 unique molecules to the Indian market and hold prominent positions in 9 therapeutic segments across regions including the EU and North America. Their product portfolio is extensive, encompassing injectables, antibiotics, antifungals, antipyretics, cardiovascular medications, central nervous system drugs, corticosteroids, gastrointestinal treatments, and nutraceuticals. They also offer pediatric formulations and vaccines. The company emphasizes quality, affordability, and innovation, reflected in their GMP certifications and numerous product patents. Their key therapeutic areas include infectious diseases, pain management, cardiology, and pediatrics, with principal dosage forms ranging from oral solutions to injections.

Manufacturer usually replies in 4 days

aprepitant

Capsules 80mg, 125mg

Dossier type
CTD
Dossier status
Under development
Country of origin
India
GMP approvals
EU GMP, WHO
Manufacturer #9258
This company is a research-driven pharmaceutical manufacturer specializing in oral solid dosage forms. They offer both pharmaceutical and nutraceutical products, including pre-formulation intermediates like granules and pellets, as well as finished formulations such as tablets, capsules, and oral thin films. Their focus is on developing differentiated generic products using innovative process technologies to enhance patient convenience and affordability. Key therapy areas include urology, cardiovascular health, infectious diseases, gastrointestinal disorders, pain management, vitamins, and skin conditions. The company holds EU-GMP certifications alongside WHO-GMP, ISO 9001, and NSF/ANSI 455-2 certifications. They operate with a robust R&D center recognized by the Indian government and collaborate with pharmaceutical companies globally for product development and marketing.

Manufacturer usually replies in 4 days

aprepitant

Capsules 80 mg, 120 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #22283
This company is a leading manufacturer of anti-cancer medications, specializing in a wide range of oncology drugs including those for solid tumors, hematology, and supportive care. They boast a portfolio of over 100 products with a focus on cost-effectiveness through in-house API development and manufacturing. The company's commitment to innovation is evident in their New Drug Delivery System (NDDS) formulations which aim to improve patient compliance and reduce medication waste. Their strong R&D pipeline promises further advancements in the oncology field. They hold WHO-GMP certifications for their API plant, enabling both domestic and international market reach. Key therapy areas include AML, Renal Cell Carcinoma, Gastro-Intestinal tumors, Pancreatic Neuroendocrine Tumors, Thyroid cancer, and Prostate cancer.

Manufacturer usually replies in 5 days

Want to see all 12 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Aprepitant

Aprepitant is a type of medicine called Antiemetics. It is used alone or with ondansetron and dexamethasone or other medications in adults or children older than 6 months to prevent nausea and vomiting which occur as after receiving cancer chemotherapy treatment. It is also used with other medications in adults and children over 6 months of age to prevent delayed nausea and vomiting that may occur several days after receiving certain types chemotherapy therapies. Aprepitant is not for controlling nausea and vomiting which could be result of other conditions. As an Antiemetic, It actions block the action of neurokinin in the brain as it causes nausea and vomiting. Aprepitant is sold under the brand name Emend among others. Merck & Co made Aprepitant. Aprepitant got its first approval from FDA and Europe in 2003. Due to its safety and efficacy record, it earned a place on the World Health Organization's List of Essential Medicines, making it one of the safest drugs to use.

Dosage and forms:

Aprepitant is available as a capsule and as an oral suspension (liquid). In the prevention of nausea and vomiting resulting from chemotherapy, the usual recommended dose is once a day, for the first few days of cancer chemotherapy. Aprepitant is administered 1 hour prior to chemotherapy on the first three days of the treatment, even if the chemotherapy is not scheduled on days 2 or 3. It is also available as an injection for the vein.

The price of Aprepitant

In USA, the consumers pay an average retail price of $109.64 for a generic version of 40 mg capsule. The price of this medicine is significantly lower in the developing world, for example, the supply of 2 tablets of 80mg cost USD20 only in India compared the higher prices in the developing world.

How does it work?

Aprepitant is NK1 antagonist. It actions block signals of NK1 receptors resulting in a in decrease in the likelihood of vomiting or nausea. NK1 is a dominant ligand called Substance P. Substance P is a neuropeptide that sends impulses and messages from the brain. Substance P occurs naturally in high concentrations in the vomiting center of our brain. When activated, it results in a vomiting reflex. It is also vital to the transmission of pain impulses from the peripheral receptors to the central nervous system of the brain. Aprepitant inhibits both the acute and delayed emesis induced by cancer chemotherapy as it actions block substance P landing on receptors in the brain's neurons. Aprepitant crosses the blood brain barrier to bind to NK1 receptors.

Finding Aprepitant Manufacturers and Suppliers

The best way to find and gain access to Aprepitant manufacturers and Aprepitant suppliers is to make through Pipelinepharma's global B2B online marketplace for medicines and other pharmaceuticals. Normally, finding trusted manufacturers and supplies of specific drugs like Aprepitant can be a time-consuming challenge, but with Pipelinepharma's simple search engine and network of proven partners, the whole process becomes a lot easier. All you need to do to get started is to make use of our integrated search engine and start looking for suppliers or manufacturers of Aprepitant to work with. You can fine-tune your search results using various filters too, letting you search for Aprepitant from specific countries.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation